RCA
ABBV icon

Resonant Capital Advisors’s AbbVie ABBV Stock Holding History

Resonant Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Sell
16,399
-436
-3% -$93.8K 0.2% 84
2026
Q1 		$3.66M Buy
16,835
+1,480
+10% +$328K 0.19% 85
2025
Q4 		$3.51M Sell
15,355
-241
-2% -$54.9K 0.19% 83
2025
Q3 		$3.61M Buy
15,596
+50
+0.3% +$10.2K 0.21% 84
2025
Q2 		$2.89M Buy
15,546
+1,009
+7% +$188K 0.18% 93
2025
Q1 		$3.05M Buy
14,537
+150
+1% +$29.2K 0.21% 84
2024
Q4 		$2.56M Sell
14,387
-121
-0.8% -$22.2K 0.19% 96
2024
Q3 		$2.87M Buy
14,508
+931
+7% +$174K 0.21% 89
2024
Q2 		$2.33M Buy
13,577
+327
+2% +$54.2K 0.19% 94
2024
Q1 		$2.41M Buy
13,250
+823
+7% +$142K 0.21% 94
2023
Q4 		$1.93M Buy
12,427
+51
+0.4% +$7.43K 0.19% 106
2023
Q3 		$1.84M Buy
12,376
+4
+0% +$587 0.2% 95
2023
Q2 		$1.67M Sell
12,372
-300
-2% -$44K 0.18% 104
2023
Q1 		$2.02M Sell
12,672
-60
-0.5% -$9.17K 0.23% 94
2022
Q4 		$2.06M Buy
12,732
+749
+6% +$115K 0.26% 92
2022
Q3 		$1.61M Buy
11,983
+348
+3% +$49.9K 0.24% 89
2022
Q2 		$1.78M Buy
11,635
+429
+4% +$65.6K 0.28% 87
2022
Q1 		$1.82M Buy
11,206
+350
+3% +$50.8K 0.27% 78
2021
Q4 		$1.47M Buy
10,856
+780
+8% +$92.1K 0.22% 85
2021
Q3 		$1.09M Buy
10,076
+842
+9% +$96.2K 0.19% 89
2021
Q2 		$1.04M Buy
9,234
+13
+0.1% +$1.46K 0.2% 86
2021
Q1 		$998K Buy
9,221
+1,310
+17% +$140K 0.21% 84
2020
Q4 		$848K Sell
7,911
-312
-4% -$30K 0.2% 86
2020
Q3 		$720K Sell
8,223
-653
-7% -$61.5K 0.21% 84
2020
Q2 		$871K Buy
8,876
+104
+1% +$9.16K 0.25% 83
2020
Q1 		$668K Buy
8,772
+341
+4% +$29K 0.24% 108
2019
Q4 		$746K Buy
+8,431
New +$700K 0.24% 117

Other funds holding ABBV

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Resonant Capital Advisors's ABBV Position: Q2 2026 in Review

Resonant Capital Advisors reduced its AbbVie (ABBV) stake by 2.6% in Q2 2026, selling an estimated $93.8K and leaving 16,399 shares worth $4.13M. The position accounts for 0.2% of the portfolio, ranked #84.

Resonant Capital Advisors first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 2,172 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Resonant Capital Advisors held 16,399 shares of AbbVie worth $4.13M as of Q2 2026.
  • Resonant Capital Advisors sold 436 AbbVie shares in Q2 2026, an estimated $93.8K.
  • AbbVie made up 0.2% of Resonant Capital Advisors's portfolio in Q2 2026, its #84 holding.
  • Resonant Capital Advisors first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 2,172 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Resonant Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.